التفاصيل البيبلوغرافية
العنوان: |
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms |
المؤلفون: |
Nannya, Yasuhito, Tobiasson, Magnus, Sato, Shinya, Bernard, Elsa, Ohtake, Shigeki, Takeda, June, Creignou, Maria, Zhao, Lanying, Kusakabe, Manabu, Shibata, Yuhei, Nakamura, Nobuhiko, Watanabe, Mizuki, Hiramoto, Nobuhiro, Shiozawa, Yusuke, Shiraishi, Yuichi, Tanaka, Hiroko, Yoshida, Kenichi, Kakiuchi, Nobuyuki, Makishima, Hideki, Nakagawa, Masahiro, Usuki, Kensuke, Watanabe, Mitsumasa, Imada, Kazunori, Handa, Hiroshi, Taguchi, Masataka, Kiguchi, Toru, Ohyashiki, Kazuma, Ishikawa, Takayuki, Takaori-Kondo, Akifumi, Tsurumi, Hisashi, Kasahara, Senji, Chiba, Shigeru, Naoe, Tomoki, Miyano, Satoru, Papaemanuil, Elli, Miyazaki, Yasushi, Hellström-Lindberg, Eva, Ogawa, Seishi |
المصدر: |
Blood Advances; July 2023, Vol. 7 Issue: 14 p3624-3636, 13p |
مستخلص: |
•Major clone sizes in posttreatment samples are strongly correlated with clinical response.•Inclusion of posttreatment clone size into the prognostic model allows better prognostication for MDS cases treated with azacitidine. |
قاعدة البيانات: |
Supplemental Index |